Can You Handle Risk? With A Dozen Clinical Trials, Exelixis Has Strong Upside Potential
By Christopher F. Davis : As a PhD-level epidemiologist and market analyst, there is no sector more interesting to me than biotech
. I have opined on several of these names in the past. Those of you who follow my work know that I search for companies that are near-completion of developing new drugs, ...
Read the rest of this article on Healthcare Sector and Stocks Analysis from Seeking Alpha